Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Detalles Bibliográficos
Autores principales: Griese, Matthias, Costa, Stefano, Linnemann, Rachel W., Mall, Marcus A., McKone, Edward F., Polineni, Deepika, Quon, Bradley S., Ringshausen, Felix C., Taylor-Cousar, Jennifer L., Withers, Nicholas J., Moskowitz, Samuel M., Daines, Cori L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020728/
https://www.ncbi.nlm.nih.gov/pubmed/32969708
http://dx.doi.org/10.1164/rccm.202008-3176LE

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020728/
https://www.ncbi.nlm.nih.gov/pubmed/32969708
http://dx.doi.org/10.1164/rccm.202008-3176LE

Ejemplares similares